JP2002500651A5 - - Google Patents

Download PDF

Info

Publication number
JP2002500651A5
JP2002500651A5 JP1999500127A JP50012799A JP2002500651A5 JP 2002500651 A5 JP2002500651 A5 JP 2002500651A5 JP 1999500127 A JP1999500127 A JP 1999500127A JP 50012799 A JP50012799 A JP 50012799A JP 2002500651 A5 JP2002500651 A5 JP 2002500651A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1999500127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500651A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK1998/000220 external-priority patent/WO1998053820A1/en
Publication of JP2002500651A publication Critical patent/JP2002500651A/ja
Publication of JP2002500651A5 publication Critical patent/JP2002500651A5/ja
Ceased legal-status Critical Current

Links

JP50012799A 1997-05-29 1998-05-28 精神分裂病及び精神病の治療方法 Ceased JP2002500651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK0620/97 1997-05-29
DK62097 1997-05-29
PCT/DK1998/000220 WO1998053820A1 (en) 1997-05-29 1998-05-28 Treatment of schizophrenia and psychosis

Publications (2)

Publication Number Publication Date
JP2002500651A JP2002500651A (ja) 2002-01-08
JP2002500651A5 true JP2002500651A5 (OSRAM) 2006-01-05

Family

ID=8095640

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50012799A Ceased JP2002500651A (ja) 1997-05-29 1998-05-28 精神分裂病及び精神病の治療方法

Country Status (10)

Country Link
US (1) US6297262B1 (OSRAM)
EP (1) EP1014974B1 (OSRAM)
JP (1) JP2002500651A (OSRAM)
AT (1) ATE273007T1 (OSRAM)
AU (1) AU7639598A (OSRAM)
DE (1) DE69825605T2 (OSRAM)
ES (1) ES2227836T3 (OSRAM)
PT (1) PT1014974E (OSRAM)
WO (1) WO1998053820A1 (OSRAM)
ZA (1) ZA984633B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
DK1766077T3 (da) 2004-06-21 2012-07-16 Univ Leland Stanford Junior Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2875674A1 (en) 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE845612A (fr) 1976-03-23 1977-02-28 Derives de tetrazole-5-carboxamide et leur preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0261763B1 (en) 1986-06-27 1994-02-09 Beecham Group Plc Novel bridged bicyclic N-heterocycles
IL83275A (en) 1986-09-08 1994-02-27 Novo Nordisk As Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them
GB8714789D0 (en) 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
US5328925A (en) 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE922270A1 (en) 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
AU674541B2 (en) 1992-08-31 1997-01-02 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
CZ181493A3 (en) 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
DK0734259T3 (da) 1993-08-19 2002-09-30 Novo Nordisk As Antipsykotisk fremgangsmåde
US5705512A (en) 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA

Similar Documents

Publication Publication Date Title
JP2000510751A5 (OSRAM)
JP2000509942A5 (OSRAM)
JP2000509637A5 (OSRAM)
JP2000509912A5 (OSRAM)
JP2000509635A5 (OSRAM)
JP2000507042A5 (OSRAM)
JP2001508083A5 (OSRAM)
JP2001526586A5 (OSRAM)
JP2002508132A5 (OSRAM)
JP2000509587A5 (OSRAM)
JP2000507369A5 (OSRAM)
JP2000507433A5 (OSRAM)
JP2001518031A5 (OSRAM)
JP2002504852A5 (OSRAM)
JP2001507937A5 (OSRAM)
JP2000510793A5 (OSRAM)
JP2000508841A5 (OSRAM)
JP2000508680A5 (OSRAM)
JP2001512633A5 (OSRAM)
JP2000509804A5 (OSRAM)
JP2000509853A5 (OSRAM)
JP2000509755A5 (OSRAM)
JP2000510969A5 (OSRAM)
JP2000508102A5 (OSRAM)
JP2000508836A5 (OSRAM)